Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?

Br J Dermatol. 2005 Oct;153(4):701-5. doi: 10.1111/j.1365-2133.2005.06899.x.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Dermatologic Agents / adverse effects*
  • Disease Models, Animal
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Neoplasms / chemically induced*
  • Tacrolimus / adverse effects*
  • Tacrolimus / analogs & derivatives*

Substances

  • Dermatologic Agents
  • Immunosuppressive Agents
  • pimecrolimus
  • Tacrolimus